Irish medtech company ProVerum has raised €30 million to support its clinical programme as it looks to go to market with its ground-breaking ProVee device in both Europe and the US.
The series A funding round was co-led by Gilde Healthcare and Lightstone Ventures, with Atlantic Bridge and other existing investors also participating.
ProVerum, which was founded by Ríona Ní Ghriallais and Conor Harkin in 2016 as a spinout from Trinity College Dublin, has developed a novel treatment solution for patients with symptomatic benign prostatic hyperplasia (BPH). This is a common condition where the prostate gland is enlarged, causing difficultly with urination and potentially kidney problems too.